sacituzumab govitecan
gilead sciences
['mbc', 'sacituzumab', 'tropics 02']
tropics 02 trial results out at asco 2022. sacituzumab compared to physician choice of chemotherapy among patients with hr +ve mbc who have progressed on endocrine therapy , cdk4/6i and chemotherapy. 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"